Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 4/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSPO | P30536 | 2/20 | 0.39 |
| ▸ | CRHBP | P24387 | 1/20 | 0.38 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8102314 | 0.84 | TSHR (0.47) | SLC6A2SLC6A4SLC6A3ALDH1A1LMNA | |
| SCHEMBL3965550 | 0.81 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3ALDH1A1TSHR | |
| SCHEMBL8101821 | 0.80 | HIF1A (0.57) | SLC6A2SLC6A4SLC6A3ALDH1A1LMNA | |
| SCHEMBL7487933 | 0.79 | ALDH1A1 (0.46) | ALDH1A1LMNATSHRKMT2AHPGD | |
| SCHEMBL3306441 | 0.79 | ALDH1A1 (0.42) | ALDH1A1LMNATSHRKMT2AHPGD | |
| SCHEMBL8540431 | 0.79 | PRMT5 (0.43) | ALDH1A1LMNATSHRKMT2AHPGD | |
| SCHEMBL30463198 | 0.79 | ALDH1A1 (0.46) | ALDH1A1LMNATSHRKMT2AHPGD | |
| SCHEMBL8102937 | 0.78 | TSHR (0.54) | SLC6A2SLC6A4SLC6A3ALDH1A1LMNA | |
| SCHEMBL1421554 | 0.77 | FOLH1 (0.58) | SLC6A2SLC6A4SLC6A3ALDH1A1TSHR | |
| SCHEMBL9776807 | 0.77 | ALDH1A1 (0.47) | ALDH1A1LMNATSHRKMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113778-A1 | PROCESS FOR PREPARING O-CHLOROMETHYLPHENYLGLYOXYLIC ESTERS, IMPROVED PROCESS FOR PREPARING (E)-2-(2-CHLOROMETHYLPHENYL)-2-ALKOXIMINOACETIC ESTERS, AND NOVEL INTERMEDIATES FOR THEIR PREPARATION | DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO KG (AT) | 2010-05-06 | — | — | US | disclosed |
| US-6124493-A | Process for the preparation of o-chloromethyl-phenylglyoxylic acid derivatives | NOVARTIS FINANCE CORPORATION (US) | 2000-09-26 | — | — | US | disclosed |
| EP-0782982-B1 | Process for the preparation of o-chloro-methyl-phenylglyoxylic acid derivatives | NOVARTIS AG (CH) | 2000-05-17 | — | — | EP | disclosed |
| US-5756811-A | Process for the preparation of o-chloromethyl-phenylglyoxylic acid derivatives | NOVARTIS CORPORATION (US) | 1998-05-26 | — | — | US | disclosed |
| EP-0782982-A1 | Process for the preparation of o-chloro-methyl-phenylglyoxylic acid derivatives | Novartis AG (CH) | 1997-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113778-A1 | PROCESS FOR PREPARING O-CHLOROMETHYLPHENYLGLYOXYLIC ESTERS, IMPROVED PROCESS FOR PREPARING (E)-2-(2-CHLOROMETHYLPHENYL)-2-ALKOXIMINOACETIC ESTERS, AND NOVEL INTERMEDIATES FOR THEIR PREPARATION | CYP4F12, GRHPR, CYP4F2 | SLC6A2 3277/4885SLC6A4 1278/4885SLC6A3 4294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.